Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more
Medigen Vaccine Biologics (6547) - Net Assets
Latest net assets as of September 2025: NT$3.61 Billion TWD
Based on the latest financial reports, Medigen Vaccine Biologics (6547) has net assets worth NT$3.61 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.07 Billion) and total liabilities (NT$461.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.61 Billion |
| % of Total Assets | 88.67% |
| Annual Growth Rate | 32.8% |
| 5-Year Change | 22.56% |
| 10-Year Change | 186.39% |
| Growth Volatility | 80.2 |
Medigen Vaccine Biologics - Net Assets Trend (2012–2024)
This chart illustrates how Medigen Vaccine Biologics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medigen Vaccine Biologics (2012–2024)
The table below shows the annual net assets of Medigen Vaccine Biologics from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.85 Billion | +0.09% |
| 2023-12-31 | NT$3.85 Billion | -23.51% |
| 2022-12-31 | NT$5.03 Billion | +7.55% |
| 2021-12-31 | NT$4.68 Billion | +48.85% |
| 2020-12-31 | NT$3.14 Billion | +129.84% |
| 2019-12-31 | NT$1.37 Billion | -15.22% |
| 2018-12-31 | NT$1.61 Billion | +5.98% |
| 2017-12-31 | NT$1.52 Billion | +3.51% |
| 2016-12-31 | NT$1.47 Billion | +9.31% |
| 2015-12-31 | NT$1.34 Billion | +24.62% |
| 2014-12-31 | NT$1.08 Billion | +135.56% |
| 2013-12-31 | NT$457.94 Million | +257.76% |
| 2012-12-31 | NT$128.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medigen Vaccine Biologics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5846500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$3.93 Billion | 102.09% |
| Total Equity | NT$3.85 Billion | 100.00% |
Medigen Vaccine Biologics Competitors by Market Cap
The table below lists competitors of Medigen Vaccine Biologics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Boston Omaha Corp
NYSE:BOC
|
$283.63 Million |
|
Meitav Trade Inv Ltd
TA:MTRD
|
$283.72 Million |
|
Shuifa Energas Gas Co Ltd
SHG:603318
|
$283.90 Million |
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
$284.05 Million |
|
Jiangsu Fasten Co Ltd
SHE:000890
|
$283.59 Million |
|
Akebia Therapeutics Inc
F:AX9
|
$283.56 Million |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
$283.54 Million |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
$283.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medigen Vaccine Biologics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,846,579,000 to 3,849,987,000, a change of 3,408,000 (0.1%).
- Net loss of 80,465,000 reduced equity.
- New share issuances of 3,466,000 increased equity.
- Other comprehensive income decreased equity by 421,769,000.
- Other factors increased equity by 502,176,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-80.47 Million | -2.09% |
| Share Issuances | NT$3.47 Million | +0.09% |
| Other Comprehensive Income | NT$-421.77 Million | -10.96% |
| Other Changes | NT$502.18 Million | +13.04% |
| Total Change | NT$- | 0.09% |
Book Value vs Market Value Analysis
This analysis compares Medigen Vaccine Biologics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.38x to 3.16x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | NT$15.52 | NT$37.00 | x |
| 2013-12-31 | NT$18.73 | NT$37.00 | x |
| 2014-12-31 | NT$10.66 | NT$37.00 | x |
| 2015-12-31 | NT$9.51 | NT$37.00 | x |
| 2016-12-31 | NT$8.40 | NT$37.00 | x |
| 2017-12-31 | NT$7.70 | NT$37.00 | x |
| 2018-12-31 | NT$7.06 | NT$37.00 | x |
| 2019-12-31 | NT$5.78 | NT$37.00 | x |
| 2020-12-31 | NT$11.29 | NT$37.00 | x |
| 2021-12-31 | NT$14.65 | NT$37.00 | x |
| 2022-12-31 | NT$15.55 | NT$37.00 | x |
| 2023-12-31 | NT$11.72 | NT$37.00 | x |
| 2024-12-31 | NT$11.71 | NT$37.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medigen Vaccine Biologics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.29%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.13x
- Recent ROE (-2.09%) is above the historical average (-17.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -17.19% | 0.00% | 0.00x | 1.17x | NT$-34.80 Million |
| 2013 | -16.77% | 0.00% | 0.00x | 1.04x | NT$-122.60 Million |
| 2014 | -9.77% | 0.00% | 0.00x | 1.13x | NT$-213.28 Million |
| 2015 | -13.52% | 0.00% | 0.00x | 1.23x | NT$-316.16 Million |
| 2016 | -14.26% | 0.00% | 0.00x | 1.24x | NT$-356.53 Million |
| 2017 | -22.37% | 0.00% | 0.00x | 1.40x | NT$-492.40 Million |
| 2018 | -29.55% | 0.00% | 0.00x | 1.35x | NT$-637.55 Million |
| 2019 | -46.59% | -56861.07% | 0.00x | 1.67x | NT$-773.52 Million |
| 2020 | -21.99% | -6002.42% | 0.00x | 1.11x | NT$-1.00 Billion |
| 2021 | 30.16% | 42.98% | 0.62x | 1.13x | NT$942.65 Million |
| 2022 | -29.86% | -411.31% | 0.05x | 1.46x | NT$-2.00 Billion |
| 2023 | -30.15% | -297.68% | 0.06x | 1.58x | NT$-1.54 Billion |
| 2024 | -2.09% | -13.29% | 0.14x | 1.13x | NT$-465.46 Million |
Industry Comparison
This section compares Medigen Vaccine Biologics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medigen Vaccine Biologics (6547) | NT$3.61 Billion | -17.19% | 0.13x | $283.60 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |